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Abstract
Nephrotic syndrome occasionally may be associated with complications of 
acquired hypercoagulable state. An eight-year-old boy with steroid responsive 
nephrotic syndrome developed his fourth relaps after nearly 15 months of 
remission. Acute neurological symptoms developed on the third day of his 
hospital stay. Cranial MRI demonstrated severe superior sagital bilateral 
transverse and rectal sinus thrombosis. Unfractionated heparin was switched 
to LMWH on the 6th day of treatment as progression-hemiparesis and seizures 
in the neurologic state were observed. Repeated MRI revealed new hyperacute 
vascular lesions. Besides the well known acquired prothrombotic state, we 
decided to search for inherited factors of procoagulant activity. We detected the 
activated Protein C rate below the lowest normal value. Furthermore, mutational 
analysis revealed heterozygous FV Leiden mutation in combination with 
prothrombin 20210A polymorphism (heterozygous mutation). LMWH followed 
by warfarin therapy led to successful complete recanalisation and neurological 
recovery. Warfarin was discontinued after 18 months follow up period. Lack of 
evidence based therapeutic protocols highlights the importance of sharing case 
reports where multiple aquired and/or genetical causes are detected.
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disturbance, repeatedly occuring seizures. Repeated MRI revealed 
new hyperacute vascular lesions on territories supplied by the right 
anterior and medial cerebral artery. The previously detected sinus 
thrombosis showed unchanged spread.
Anticoagulant therapy was immediately changed to LMWH 
administration (2mg/kg/day). 11 days after the admission, on 
reaching the desired level of anticoagulation warfarin was added 
with successful control of PT while LMWH was withdrawn Warfarin 
administration was discontinued after 18 months of problem free 
period.
The child gradually made a complete clinical recovery, proteinuria 
ceased by the end of the second week of steroid treatment, with no 
relapse occuring after withdrawal of steroid therapy. Cranial MRI 
performed 11 months later showed complete recanalisation with 
regularly filling sinuses (Figure 3).
Besides the well known acquired prothrombotic state, we decided 
to search for inherited causes of increased procoagulant activity. 
With functional tests we detected Protein S and ATIII activity 
within the reference range, however Protein C activity and activated 
Protein C rate remained below the lowest normal values. Further 
molecular genetic investigation, using nucleic acid hybridization 
assays, confirmed the diagnosis of heterozygous FV Leiden mutation 
that was suspected by previous APC resistance testing method. 
Prothrombin 20210A polymorphism analysis verified heterozygous 
mutation (Figure 1), but the presence of lupus “anticoagulant” was 
excluded.
Case Presentation
An eight-year-old boy with Steroid Sensitive Nephrotic 
Syndrome (SSNS) developed his fourth relaps after nearly 15 months 
of remission phase. He was diagnosed with Nephrotic Syndrome (NS) 
at the age of 4 and had experienced three steroid responsive relapses 
Family history is unremarkable.
On admission the patient was hospitalized with relapse of 
nephrotic syndrome and was treated with oral steroid at a dose of 60 
mg/m2/day.
On the third day of his hospital stay he acutely developed severe 
headache, somnolent state followed by vomiting and seizures.
Coagulation studies showed the following parameters: 
Prothrombin Time (PT) of 8.2 sec (controll: 8.8 sec), an Activated 
Partial Thromboplastin Time (APTT) of 25, 2 sec (controll: 29, 2 sec), 
a Thrombin Time (TT) of 24.3 sec (controll: 18.2 sec), an INR of 0.97, 
a D-dimer of 33.85 mg/L FEU, a positive fibrin monomer test, an FDP 
of higher than 20 mg/L, and a platelet count of 224 G/L.
Cranial MRI demonstrated superior sagittal, bilateral transverse- 
and rectal sinus thrombosis (Figure 2).
A loading dose of Un-Fractionated-Heparin (UFH) of 75 U/kg 
was given IV, followed by a continous infusion of 15-25 U/kg/hour. 
We attempted to maintain the APTT between 70 to 90 sec, with a 
control of 32 sec.
On the 6th day of his treatment the boy developed new symptoms: 
left sided hemiparesis with faciobrachial dominance, transient visual 
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Conclusion
NS is known to be associated with a hypercoagulable state and 
thromboembolic complications, however such episodes are reportedly 
less frequent in children than adults [1,2]. Thrombotic Episodes (TE) 
have been reported in patients with established glomerular disease 
based on activation of the hemostatic system with a complex interplay 
between increased hepatic synthesis and intravascular consumption 
of coagulation factors and increased urinary loss of proteins.
Higher incidence of TE was reported in adults with membranous 
nephropathy. Children with secondary form of NS have a higher 
incidence of TE than those with minimal change disease [3]. Studies, 
like the Mid-West Pediatric Nephrology Consortium (MWPNC) 
Study [3], reported 9.2% prevalence of venous thromboembolic event 
in the examined group. Similar data was shown in a recent report by 
Bryce A Kerlin [4].
Higher risk of TE in NS, especially within the first 3-6 months, has 
been reported by Mahmoodi BK [5]. Intravascular hypovolemia due 
to hypoalbuminemia and the use of steroid are important risk factors 
of thrombosis development. Therefore, thromboprophylaxis may 
be indicated in selected cases especially with high grade proteinuria 
in the early weeks after diagnosis. Most clinicians do not give 
prophylactic anticoagulation initially. The incidence of TE tends to 
increase in case of serum albumin concentration <20g/L, fibrinogen 
level >6g/L, antithrombin III level <70% of the normal, in neonates 
and adolescents with systemic vasculitis associated “secondary” NS 
[3,6]. Among the prophilactic strategies, some authors suggested 
using aspirin [7], but in vitro observations shows it less beneficial, 
and there are no controlled trials confirming its efficacy [8]. Another 
choice for oral profilactic therapy can be warfarin.
Our patient had consolidated laboratory alterations and quick 
response to previous steroid treatments by the time promised a rather 
“low risk” SSNS patient with modest nephrotic range proteinuria.
The initial treatment was UFH. Available trials in pediatric 
patients that evaluate the efficacy of UFH compared to LMWH 
found no significant difference in the outcome [9]. However, LMWH 
seems preferable because of the lower side effect rate. In our case the 
child developed new intracranial vascular lesions six days after the 
initation of UFH. However, after switching anticoagulation method 
to LMWH a convincing clinical improvement and complete recovery 
was observed. LMWH therapy was followed by prolonged oral 
anticoagulation with warfarin, when nephrotic-range proteinuria 
disappeared and the albumine level stabilized above 25g/l. Total 
recanalisation of the affected sinuses were reached successfully (Figure 
3). Thromboembolic phenomenon in NS has been attributed mainly to 
low plasma AT III levels [10], although such events has been reported 
with normal AT III levels as well [11]. Higher fibrinogen levels has 
Figure 1: Factor V Leiden heterozygous mutation (A) Prothrombin 20210A 
allel heterozyguos mutation (B) In the case of our patient, compared with wild 
type, homozygous and heterozygous controlls-hybridisation assay.
Figure 2: Acute sinus thrombosis in the sinus sagittal superior, rectus and 
bilateral transversus.
Figure 3: Regularly filled sinuses. Complete recanalisation of the superior, 
rectus and both transverse sinuses.
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been detected in serum of NS patients in relapse, such alterations 
were attributed to hyperthrombotic state observed in these patients. 
Variable levels of protein C and S has been measured in NS patients 
as well, and there have been conflicting reports published concerning 
alterations in functional activity of protein C [12]. We detected the 
APC rate below the lowest normal value in relapse, however upon 
stable remission such alteration in PC value was not observed.
Loss of AT III in the nephrotic urine may be an important cause 
of the failure of anticoagulation with heparin. Large amounts of 
administered heparin may also be lost in the nephrotic urine. LMWH 
has a lot of difference from UFH in its anticoagulant mechanism, let 
alone the different antifactor Xa to antifactor IIa ratios.
Finally, about our interesting findings of genetic factors. Beyond 
obvious acquired prothrombotic state in NS, screening for genetical 
background may be indicated in selected cases. It is no doubt to search 
for genetic background if a previously healthy child experiences a TE. 
Similarly, predisposing thrombophylic factors are to be searched for 
when a child with nephrotic syndrome has thrombotic complication 
when no obvious explanation (high grade proteinuria, severe 
hypovolemia etc.) for such an event exist. Some authors found a 
synergic interaction between increased prothrombin levels caused 
by 20210A mutation and delayed inactivation of FV Leiden substrate 
[13]. Others believe that clinicians must decide about testing 
thrombophilia in every case of TE in affected children, or only with 
positive familial history of thrombosis [14]. Usually small children 
with thrombosis have both hereditary and acquired factors. According 
to the American College guideline about antithrombotic therapy and 
prevention of thrombosis in children, knowlegde of background 
factors does not really influence the therapeutic recommendations 
[15]. Lack of evidence based therapeutic protocols highlights the 
importance of sharing case reports where multiple aquired and/or 
genetical causes are detected. Long term anticoagulation is indicated 
in adult patients with serious TE associated with NS especially when 
genetical predisposing factor(s) are detected. However, there are 
no clear therapeutic recommendations for similar cases in children 
with NS. It might be justified to perform basic genetic testing among 
pediatric patients with NS, who once faced with thromboembolism, 
even if aquired predisposing factors are already at hand.
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